Company intelligence / Profile preview

Apreo Health

Menlo Park, California, United Statessante.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Apreo Health has completed first-in-human, multicenter feasibility studies ("BREATHE 1&2") for its BREATHE Airway Scaffold, enrolling 60 patients across five sites in Australia and Europe. Six-month data demonstrated early feasibility, safety, and efficacy—showing improvements in lung function, symptoms, and quality of life without the risk of pneumothorax. The therapy is designed to be tissue-sparing and broadly applicable to severe emphysema patients with hyperinflation who are underserved by current interventions[1][3].

Therapeutic areas: Pulmonology
Modalities: DeviceImplantable medical device (Airway Scaffold)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Apreo Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apreo Health.

Explore the full profile